Delivery Order SPE2DB22D2211-SPE2DB25FSFZK
- Not listed
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a $2,793.70 firm fixed-price delivery order for 100-unit vials of Xeomin on July 11, 2025, with an ultimate completion date of August 1, 2025. The order will be fulfilled at the company's corporate office location in Conshohocken, Pennsylvania. This competitively awarded delivery order carries no set-aside designation and represents a child contract under AmerisourceBergen's larger federal contract portfolio with the DLA. This...
- The Defense Logistics Agency awarded a delivery order valued at $8,381.10 to AmerisourceBergen Drug Corp for 100-unit vials of Xeomin, a botulinum toxin-based therapeutic product used for medical applications. This non-set-aside, competitively awarded contract is issued under a firm fixed price structure with an ultimate completion date of September 19, 2025. The order will be fulfilled from AmerisourceBergen's Conshohocken, Pennsylvania facility, where the company maintains its corporate...
- The Defense Logistics Agency awarded a $46,934.16 firm fixed price delivery order to AmerisourceBergen Drug Corp on September 8, 2025, for 200-unit vials of Xeomin, with an ultimate completion date of September 29, 2025. This non-set-aside contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999,999,999.00...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 18, 2025, for the supply of Xeomin 100 Unit Vials, with a ceiling value of $5,989.62 and an ultimate completion date of October 9, 2025. This is a firm fixed price delivery order with no set-aside designation, competitively awarded under an open procurement process. The place of performance is AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania, where the company serves as a...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $6,984.25 for 100-unit vials of Xeomin on July 28, 2025, with an ultimate completion date of August 18, 2025. This firm fixed-price contract, which carries no set-aside designation, will be performed in Conshohocken, Pennsylvania, where the vendor maintains its corporate headquarters. Xeomin is a botulinum toxin product used for therapeutic and cosmetic applications, and this delivery order represents a...
- The Defense Logistics Agency awarded a $1,676.22 delivery order to AmerisourceBergen Drug Corp for 100-unit vials of Xeomin, a botulinum toxin product commonly used for therapeutic and cosmetic medical applications. This firm fixed-price delivery order, issued on September 2, 2025, with an ultimate completion date of September 23, 2025, represents a child contract under AmerisourceBergen's larger pharmaceutical supply agreement. The award was made through open competition with no set-aside...
- This delivery order, valued at $27,937.00, was awarded on July 14, 2025, by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp for the supply of Xeomin 200 Unit Vials, with an ultimate completion date of August 4, 2025. The contract carries firm fixed pricing and represents a non-competitive set-aside delivery order issued under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999.99 billion global pharmaceutical support...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 29, 2025, for the supply of Xeomin 100 unit vials valued at $6,704.88 with a firm fixed price structure. The order is scheduled for completion by August 19, 2025, and will be fulfilled from the vendor's Conshohocken, Pennsylvania location. This delivery order represents a child contract issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a...
- The Defense Logistics Agency (DLA) awarded AmerisourceBergen Drug Corp a delivery order valued at $14,527.24 for 200-unit vials of Xeomin on September 23, 2025, with an ultimate completion date of October 15, 2025. This firm fixed-price, non-set-aside contract represents a direct order under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), which carries a $999.999 billion ceiling and extends through December 2026. The work will be performed...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 18, 2025, for the supply of Xeomin 100 Unit Vials, with a ceiling value of $23,467.08 and a firm fixed price structure. This is a non-set-aside, competitively awarded contract with an ultimate completion date of October 9, 2025. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform the work at its Corporate Office location. This...
- SPE2DB22D2211Indefinite Delivery Contract
- SPE2DB22D2211-SPE2DB25FSFZKDelivery Order
The Defense Logistics Agency awarded a $8,381.10 delivery order to AmerisourceBergen Drug Corp for 100-unit vials of Xeomin on September 25, 2025, with an ultimate completion date of October 17, 2025. This competitively awarded, firm fixed-price contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The contract does not utilize a set-aside designation and specifies performance at the vendor's Conshohocken, Pennsylvania facility. This order exemplifies AmerisourceBergen's role as a critical pharmaceutical distributor within the federal medical supply chain, supporting military healthcare requirements. Xeomin, a botulinum toxin product used for medical and aesthetic applications, falls within the company's established portfolio of specialty pharmaceutical deliveries to defense and veteran healthcare systems. As a major pharmaceutical distributor and healthcare solutions provider, AmerisourceBergen maintains extensive federal contracting relationships with the DLA and Defense Health Agency, delivering a comprehensive range of medications, vaccines, and medical supplies across multiple therapeutic domains to support military personnel and beneficiaries worldwide.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $8.4k | 9/25/25 |